{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,12]],"date-time":"2026-04-12T06:39:50Z","timestamp":1775975990939,"version":"3.50.1"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2014,4,9]],"date-time":"2014-04-09T00:00:00Z","timestamp":1397001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2014,4,9]],"date-time":"2014-04-09T00:00:00Z","timestamp":1397001600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Chemother Pharmacol"],"published-print":{"date-parts":[[2014,6]]},"DOI":"10.1007\/s00280-014-2459-z","type":"journal-article","created":{"date-parts":[[2014,4,8]],"date-time":"2014-04-08T20:45:30Z","timestamp":1396989930000},"page":"1227-1239","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":71,"title":["An open-label single-arm, phase II trial of zalutumumab, a human monoclonal anti-EGFR antibody, in patients with platinum-refractory squamous cell carcinoma of the head and neck"],"prefix":"10.1007","volume":"73","author":[{"given":"Vassiliki","family":"Saloura","sequence":"first","affiliation":[]},{"given":"Ezra E. W.","family":"Cohen","sequence":"additional","affiliation":[]},{"given":"Lisa","family":"Licitra","sequence":"additional","affiliation":[]},{"given":"Salem","family":"Billan","sequence":"additional","affiliation":[]},{"given":"Jose","family":"Dinis","sequence":"additional","affiliation":[]},{"given":"Steen","family":"Lisby","sequence":"additional","affiliation":[]},{"given":"Thomas C.","family":"Gauler","sequence":"additional","affiliation":[]}],"member":"297","published-online":{"date-parts":[[2014,4,9]]},"reference":[{"key":"2459_CR1","unstructured":"Ferlay J, Bray F, Pisani P, Parkin DM (2004) Globocan 2002: cancer incidence, mortality and prevalence worldwide. IARC Cancerbase No. 5. Version 2.0. IARCPress, Lyon"},{"key":"2459_CR2","doi-asserted-by":"publisher","first-page":"1116","DOI":"10.1056\/NEJMoa0802656","volume":"359","author":"JB Vermorken","year":"2008","unstructured":"Vermorken JB, Mesia R, Rivera F et al (2008) Platinum-based chemotherapy plus cetuximab in head and neck cancer. M Engl J Med 359:1116\u20131127","journal-title":"M Engl J Med"},{"key":"2459_CR3","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1016\/j.clon.2005.02.014","volume":"17","author":"X Leon","year":"2005","unstructured":"Leon X, Hitt R, Constenla M et al (2005) A retrospective analysis of the outcome of patients with recurrent and\/or metastatic squamous cell carcinoma of the head and neck refractory to a platinum-based chemotherapy. Clin Oncol R Coll Radiol 17:418\u2013424","journal-title":"Clin Oncol R Coll Radiol"},{"issue":"16","key":"2459_CR4","doi-asserted-by":"publisher","first-page":"2171","DOI":"10.1200\/JCO.2006.06.7447","volume":"25","author":"JB Vermorken","year":"2007","unstructured":"Vermorken JB, Trigo J, Hitt R et al (2007) Open-label, uncontrolled, multicenter phase II study to evaluate the efficacy and toxicity of cetuximab as a single agent in patients with recurrent and\/or metastatic squamous cell carcinoma of the head and neck who failed to respond to platinum-based therapy. J Clin Oncol 25(16):2171\u20132177","journal-title":"J Clin Oncol"},{"key":"2459_CR5","first-page":"7350","volume":"62","author":"KK Ang","year":"2002","unstructured":"Ang KK, Berkey BA, Tu X et al (2002) Impact of epidermal growth factor receptor expression on survival and pattern of relapse in patients with advanced head and neck carcinoma. Cancer Res 62:7350\u20137356","journal-title":"Cancer Res"},{"key":"2459_CR6","doi-asserted-by":"publisher","first-page":"824","DOI":"10.1093\/jnci\/90.11.824","volume":"90","author":"JR Grandis","year":"1998","unstructured":"Grandis JR, Melhem MF, Gooding WE et al (1998) Levels of TGF-alpha and EGFr protein in head and neck squamous cell carcinoma and patient survival. J Natl Cancer Inst 90:824\u2013832","journal-title":"J Natl Cancer Inst"},{"key":"2459_CR7","doi-asserted-by":"publisher","first-page":"1589","DOI":"10.1111\/j.1349-7006.2008.00861.x","volume":"99","author":"MA Sheikh Ali","year":"2008","unstructured":"Sheikh Ali MA, Gunduz M, Nagatsuka H et al (2008) Expression and mutation analysis of epidermal growth factor receptor in head and neck squamous cell carcinoma. Cancer Sci 99:1589\u20131594","journal-title":"Cancer Sci"},{"key":"2459_CR8","doi-asserted-by":"publisher","first-page":"1193","DOI":"10.1245\/s10434-007-9771-3","volume":"15","author":"Q Wei","year":"2008","unstructured":"Wei Q, Sheng L, Shui Y, Hu Q, Nordgren H, Carlsson J (2008) EGFr, HER2, and HER3 expression in laryngeal primary tumors and corresponding metastases. Ann Surg Oncol 15:1193\u20131201","journal-title":"Ann Surg Oncol"},{"key":"2459_CR9","doi-asserted-by":"publisher","first-page":"6109","DOI":"10.1073\/pnas.0709477105","volume":"105","author":"JJL van Bueren","year":"2008","unstructured":"van Bueren JJL, Bleeker WK, Brannstrom A et al (2008) The antibody zalutumumab inhibits epidermal growth factor receptor signaling by limiting intra- and intermolecular flexibility. Proc Natl Acad Sci USA 105:6109\u20136114","journal-title":"Proc Natl Acad Sci USA"},{"key":"2459_CR10","doi-asserted-by":"publisher","first-page":"4699","DOI":"10.4049\/jimmunol.173.7.4699","volume":"173","author":"WK Bleeker","year":"2004","unstructured":"Bleeker WK, van Bueren JJL et al (2004) Dual mode of action of a human anti-epidermal growth factor receptor monoclonal antibody for cancer therapy. J Immunol 173:4699\u20134707","journal-title":"J Immunol"},{"issue":"1","key":"2459_CR11","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.radonc.2007.06.007","volume":"85","author":"L Bastholt","year":"2007","unstructured":"Bastholt L, Jensen K et al (2007) Phase I\/II clinical and pharmacokinetic study evaluating a fully human monoclonal antibody against EGFr (HuMax-EGFr) in patients with advanced squamous cell carcinoma of the head and neck. Radiother Oncol 85(1):24\u201328","journal-title":"Radiother Oncol"},{"issue":"4","key":"2459_CR12","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1016\/S1470-2045(11)70034-1","volume":"12","author":"JP Machiels","year":"2011","unstructured":"Machiels JP, Subramanian S, Ruzsa A et al (2011) Zalutumumab plus best supportive care versus best supportive care alone in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck after failure of platinum-based chemotherapy: an open-label, randomised phase 3 trial. Lancet Oncol 12(4):333\u2013343","journal-title":"Lancet Oncol"},{"key":"2459_CR13","doi-asserted-by":"publisher","first-page":"1544","DOI":"10.1002\/cncr.24088","volume":"115","author":"M Peeters","year":"2009","unstructured":"Peeters M, Siena S, Van Cutsem E et al (2009) Association of progression-free survival, overall survival and patient-reported outcomes by skin toxicity and KRAS status in patients receiving panitumumab monotherapy. Cancer 115:1544\u20131554","journal-title":"Cancer"},{"key":"2459_CR14","doi-asserted-by":"crossref","first-page":"3554","DOI":"10.1200\/jco.2006.24.18_suppl.3554","volume":"24","author":"S Tejpar","year":"2007","unstructured":"Tejpar S, Peeters M, Humblet Y et al (2007) Phase I\/II study of cetuximab dose-escalation in patients with metastatic colorectal cancer (mCRC) with no or slight skin reaction on cetuximab standard dose treatment (EVEREST): pharmacokinetic (PK), pharmacodynamics (PD) and efficacy data. Proc Am Soc Clin Oncol 24:3554","journal-title":"Proc Am Soc Clin Oncol"},{"key":"2459_CR15","doi-asserted-by":"publisher","first-page":"5235","DOI":"10.1200\/JCO.2005.00.6916","volume":"23","author":"R Perez-Soler","year":"2005","unstructured":"Perez-Soler R, Saltz L (2005) Cutaneous adverse effects with HER1\/EGFr-targeted agents: is there a silver lining? J Clin Oncol 23:5235\u20135246","journal-title":"J Clin Oncol"},{"key":"2459_CR16","first-page":"3766","volume":"7","author":"L Saltz","year":"2001","unstructured":"Saltz L, Rubin MS, Hochster H (2001) Acne-like rash predicts response in patients with cetuximab (IMC-225) plus irinotecan (CPT-11) in CPT-11-refractory colorectal cancer (CRC) that expresses epidermal growth factor receptor (EGFr). Clin Cancer Res 7:3766","journal-title":"Clin Cancer Res"},{"key":"2459_CR17","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/S1470-2045(09)70311-0","volume":"11","author":"JA Bonner","year":"2010","unstructured":"Bonner JA, Jarari PM, Giralt J et al (2010) Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomized trial, and relation between cetuximab-induced rash and survival. Lancet Oncol 11:11\u201328","journal-title":"Lancet Oncol"},{"key":"2459_CR18","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1056\/NEJMoa053422","volume":"354","author":"JA Bonner","year":"2006","unstructured":"Bonner JA, Harari PM, Giralt J, Azarnia N, Shin DM, Cohen RB et al (2006) Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 354:567\u2013578","journal-title":"N Engl J Med"},{"key":"2459_CR19","doi-asserted-by":"publisher","first-page":"1212","DOI":"10.1158\/1078-0432.CCR-03-0564","volume":"10","author":"MH Cohen","year":"2004","unstructured":"Cohen MH, Williams GA, Sridhara R et al (2004) United States Food and Drug Administration drug approval summary: gefitinib (ZD1839; Iressa) tablets. Clin Cancer Res 10:1212\u20131218","journal-title":"Clin Cancer Res"},{"issue":"suppl 2","key":"2459_CR20","doi-asserted-by":"publisher","first-page":"S18","DOI":"10.1038\/sj.bjc.6602063","volume":"91","author":"P Camus","year":"2004","unstructured":"Camus P, Kudoh S, Ebina M (2004) Interstitial lung disease associated with drug therapy. Br J Cancer 91(suppl 2):S18\u2013S23","journal-title":"Br J Cancer"},{"issue":"16","key":"2459_CR21","doi-asserted-by":"publisher","first-page":"2549","DOI":"10.1200\/JCO.2005.04.9866","volume":"24","author":"M Ando","year":"2006","unstructured":"Ando M, Okamoto I, Yamamoto N, Takeda K, Tamura K, Seto T, Ariyoshi Y, Fukuoka M (2006) Predictive factors for interstitial lung disease, antitumor response, and survival in non-small-cell lung cancer patients treated with gefitinib. J Clin Oncol 24(16):2549\u20132556","journal-title":"J Clin Oncol"},{"issue":"8","key":"2459_CR22","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.1016\/j.cellsig.2009.02.021","volume":"21","author":"V Ratushny","year":"2009","unstructured":"Ratushny V, Astsaturov I, Burtness BA, Golemis EA, Silverman JS (2009) Targeting EGFR resistance networks in head and neck cancer. Cell Signal 21(8):1255\u20131268","journal-title":"Cell Signal"},{"issue":"6","key":"2459_CR23","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1016\/j.drup.2011.08.002","volume":"14","author":"R Mehra","year":"2011","unstructured":"Mehra R, Serebriiskii IG, Dunbrack RL Jr, Robinson MK, Burtness B, Golemis EA (2011) Protein-intrinsic and signaling network-based sources of resistance to EGFR- and ErbB family-targeted therapies in head and neck cancer. Drug Resist Updat 14(6):260\u2013279","journal-title":"Drug Resist Updat"},{"key":"2459_CR24","doi-asserted-by":"publisher","unstructured":"Young NR, Liu J, Pierce C, et al (2012) Molecular phenotype predicts sensitivity of squamous cell carcinoma of the head and neck to epidermal growth factor receptor inhibition. Mol Oncol. doi:10.1016\/j.molonc.2012.11.001","DOI":"10.1016\/j.molonc.2012.11.001"},{"issue":"9","key":"2459_CR25","doi-asserted-by":"publisher","first-page":"2489","DOI":"10.1158\/1078-0432.CCR-09-2318","volume":"16","author":"LF Chen","year":"2010","unstructured":"Chen LF, Cohen EE, Grandis JR (2010) New strategies in head and neck cancer: understanding resistance to epidermal growth factor receptor inhibitors. Clin Cancer Res 16(9):2489\u20132495","journal-title":"Clin Cancer Res"}],"container-title":["Cancer Chemotherapy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-014-2459-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00280-014-2459-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-014-2459-z","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-014-2459-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,29]],"date-time":"2022-07-29T01:42:05Z","timestamp":1659058925000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00280-014-2459-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,4,9]]},"references-count":25,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2014,6]]}},"alternative-id":["2459"],"URL":"https:\/\/doi.org\/10.1007\/s00280-014-2459-z","relation":{},"ISSN":["0344-5704","1432-0843"],"issn-type":[{"value":"0344-5704","type":"print"},{"value":"1432-0843","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,4,9]]},"assertion":[{"value":"31 October 2013","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 March 2014","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 April 2014","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}